Ovid Therapeutics Inc. (OVID) Income Statement

The extreme quarter-to-quarter revenue volatility, with a -88.3% decline in 2026Q2, suggests the company lacks a stable commercial product and is likely dependent on milestone or collaboration payments. This pattern makes forecasting extremely difficult and underscores the pre-commercial nature of the core pipeline. Investors should monitor for any sustained revenue base to emerge from recent clinical progress.

The 100% gross margin is a mathematical artifact of having virtually no product revenue or associated direct costs. This metric is meaningless for evaluating Ovid's future profitability as a commercial entity. The critical question for analysts is what the gross margin structure will look like once a product is launched, which remains entirely unknown based on current financials.

R&D spending is the primary driver of operating losses, dwarfing SG&A in most periods. The fluctuation in R&D spend, such as the spike to $12.6M in 2024Q2, likely corresponds to specific clinical trial milestones or activities. This cost structure is typical for a clinical-stage biotech but highlights the significant ongoing cash burn required to advance the pipeline.

The company exhibits severe negative operating leverage, as its fixed cost base (R&D and SG&A) generates substantial losses on a minimal revenue foundation. There is no evidence of operating income scaling with revenue; instead, losses appear driven by the investment cycle. This dynamic will persist until a product achieves meaningful commercial scale.